Study Summary
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.
Want to learn more about this trial?
Request More InfoInterventions
anti-CD133-CAR vector-transduced T cellsBIOLOGICAL
genetically engineered lymphocyte therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital | Beijing | Beijing Municipality | China |